



Biographical Sketch:

NAME: Elena Ranieri, Ph.D. **BIRTH DATE:** April 9, 1963

POB: Bari, ITALY

HOME ADDRESS: Via delle Magnolie, 68 **CITIZENSHIP:** ITALIAN
Borgo Lagogemolo (Bari), Italy
70020 Cassano Murge
T# +39 0881 732611

BUSINESS Chair of Clinical Pathology, Department of Medical Sciences and Surgery,
Center of Molecular Medicine
University of Foggia, Italy

ADDRESS: University of Foggia, Italy
Policlinico Riuniti
Viale Luigi Pinto, 1
71100 Foggia, Italy
T# +39 0881 732611
FAX# +39 0881 732627
e-mail elena.ranieri@unifg.it

Publications : 442 publications, 130 edited on international journals. **Original papers: 100** (Journal Citation Report (ISI). (Total Impact factor > 480; impact factor mean: 5,08; H index :35; total citations : 4530 on 19.6.20).

Elena Ranieri is Full Professor of Clinical Pathology at the University of Foggia, Italy and she has been Assistant Professor of Surgery at the University of Pittsburgh Medical Center, PA, USA and Lab Head of the Laboratory of Nephrology at the University of Bari. Elena Ranieri, PhD has been a Visiting Research Associate at Case Western Reserve University, Cleveland Ohio in 1990 and Research Associate at the University of Pittsburgh from 1997 to 2000.

She studied cellular and molecular mechanisms in the pathogenesis of glomerulonephritis and in the progression of renal damage. In the last 20 years, her scientific research has been focused on translational studies designed to generate more effective anti-cancer immunotherapies.

These studies have been segregated into three main areas: 1) identification of tumor-associated antigens, and most recently, 2) examination of host dendritic cells as a biologic adjuvants capable of promoting heightened anti-tumor immunity when provided in the therapeutic setting, 3) biomarker discovery in kidney cancer.

She has extensive research experience in immunology of renal disease and renal cancer (DC-based in vitro T cell activation and immunotherapy). She is experienced in grant management and has supervised over 40 PhD students and post-doctoral fellows, as well as MD-PhD students in Italy and USA.

She has a smooth running laboratory with a focus on tumor immunology, immunochemical and molecular biology approaches and rare diseases (Fabry-Anderson Disease and rare renal diseases).

As regards proteomics, she coordinates the research activity of the Proteomics and Mass Spectrometry core facility of the Department of Medical and Surgical Sciences for the characterization of the protein profiles of biological fluids and Renal cancer derived cell lines by means of 2D-PAGE, Mass Spectrometry (MALDI-TOF-MS e nano-HPLC-ESI-MS/MS) and SELDI-TOF-MS.

EDUCATION AND TRAINING

UNDERGRADUATE:

1982-1988 B.S. Biological Sciences, University of Bari, ITALY

GRADUATE:

1990-1992 Ph.D. in "Clinical Pharmacology and Medical Therapy", University of Bari, ITALY

POST-GRADUATE:

2003-2004 MASTER PROLEAD : Project Leader of R&D programs training, University of Bari and TecnoPolis CSATA, Ministero dell'Istruzione, dell'Universita' e della Ricerca (12 months, 724 hrs), Italy.

2003-2004 Lab Head of "Confocal Microscopy and Laser Microdissection Facility", Dept. of Emergency and Organ Transplantation University of Bari, Italy

2000-2004 Lab Head, Surgery Lab, Dept. of Emergency and Organ Transplantation, University of Bari, Italy

2000-2004 Lab Head, Tumor Immunology, immunotherapy and renal diseases, Dept. of Emergency and Organ Transplantation University of Bari, Italy

1997-2000 Research Associate, Department of Surgery, University of Pittsburgh School of Medicine Pittsburgh, PA, USA (Lab of W. Storkus, Ph.D.)

1995-96 Specialization Course on "Biology of Reproduction in humans and animal models" - Gene Therapy, University of Bari, Italy

1994-1995 Post-Doctoral Program in Clinical Pharmacology and Medical Therapy, University of Bari, ITALY

APPOINTMENTS AND POSITIONS ACADEMIC:

2019-pres Full Professor of Clinical Pathology, University of Foggia.

2012-pres President of Nursing School, triennial specialized degree, University of Foggia, Italy

2019-pres **European projects evaluator. Horizon 2020 Marie Skłodowska-Curie Actions (MSCA) Individual Fellowships (IF).**

2018-pres Member of the Board of the National Nursing Commission, Permanent Commission of Health Professions.

2013 - 2017 College Member of the School of Doctorate, "Health Food Innovation and Management", School of Medicine, University of Foggia, Italy

2012	European projects evaluator. Area 2.1.1-1 -Omics for rare diseases, FP7-HEALTH-2012-INNOVATION-1
2010	Council Member of the School of Doctorate, “Translational Medicine”, School of Medicine, University of Foggia.
2009	Member of the Scientific Technical Committee (CTS), for the european project “I.R.F.-Improve the Research activities of Foggia University by an action plan aimed to upgrade and reinforce its RTD potential”.
2008- 2013	Member of the Scientific Committee of the University of Foggia
2008- 2013	Delegate of The Rector to International Relationships of the University of Foggia
2008-2013	Delegate of The Rector to International Relationships of the University of Foggia, Faculty of Medicine
2007-pres	Chief of the Core Facility of Proteomics at Bioagromed, Interdepartmental Centre of Research, University of Foggia, Italy (2007-2010)
2007-2010	Member of the Technical- Scientific Committee of Bioagromed, Interdepartmental Centre of Research, University of Foggia, Italy
2005-2011	Professor of Molecular Pathology, School of Biotechnology, University of Bari, Italy
2005-pres	Chief of the Clinical Pathology Lab, Molecular Center for Rare Diseases, University of Foggia and Ospedali Riuniti, Foggia, Italy
2005-2019	Associate Professor of Clinical Pathology, Dept. of Biomedical Sciences, University of Foggia, Italy
2000-2004	Adjunct Assistant Professor, Dept. of Surgery University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
1997-2000	Research Associate, (Prof. W.J. Storkus) Dept. of Surgery University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
1997-99	Professor of Molecular Biology Diploma di Laurea breve per Tecnico di Laboratorio Biomedico School of Medicine, University of Bari, Bari, Italy
1993-1996	Professor of Laboratory Instrumentation Diploma di Laurea breve per Tecnico di Laboratorio Biomedico School of Medicine, University of Bari, Bari, Italy
1990	Research Associate, Institute of Pathology (Chairman: M. Lamm, M.D.) Section of Renal Immunopathology (Director: S. Emancipator, M.D.) Case Western Reserve University, School of Medicine, Cleveland, OH, USA
1988-1989	Intern Student, Division of Nephrology University of Bari, Bari, ITALY (Prof. F.P. Schena)

HONORS AND AWARDS

1996	American Society of Nephrology Travel Grant
1995-97	Associazione per il Progresso Scientifico in Nefrologia e Trapianti (APSNT)
1989-1989	Master Pharma Research Fellowship
1989	National Board to Practice Biological Science

MEMBERSHIPS

- Italian Society of Nephrology (SIN) **2002**
- European Macrophage & Dendritic Cell Society dal **2002**
- Italian Society of Clinical Immunology and Allergology (SIICA)**2004 -2010**
- **SIPMeL**, Italian Society of Clinical Pathology Laboratory Medicine **2017**
- **SIPMeT**, Italian Society of Clinical Pathology and Translational Medicine **2018**

- Puglia Regional Board: **SIPMeL member of the National Council 2018**
- Member of the **SIN-AIOM** committee **2017**
- Executive: Secretary of the Scientific Committee of the study group of **Cell Biology of the Italian Society of Nephrology 1997-2000**

RESEARCH

1. GRANTS RECEIVED

Co-Investigator and Project Leader. Progetto FIRB 2011-2015. **Project title: Innovative strategy and high technology for the study of renal cell carcinoma. Use of “OMICS” and of the system biology for the development of novel biomarkers (CAROMICS).** Protocol: **RBAP11B2SX.** (Grant: 1.419.000,00 €). Project Leader: **Prof. Francesco Paolo Schena,** University of Bari Aldo Moro).

Co-Investigator. Progetto PharmaCog, FP7 2010. Project title “Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development” (Partner 12). (Project leader: C. Babiloni, Università di Foggia).

Co-Investigator and Project Leader. Regional Project of Lab Network, 2009. **Project title:** Establishment of regional lab network for system biology approaches in human diseases. (BISIMANE), (Grant received: 1.970.560,00 €). (Project leader: Prof. F.P. Schena, University of Bari).

Principal Investigator. Progetto Fondazione Cassa di Risparmio di Puglia 2008. **Project title:** Application of proteomic techniques to study chronic renal diseases: identification of novel early biomarkers of renal damage to develop diagnostic kits for therapeutic monitoring. (Finanziamento ammesso : 50.000,00 €). (Project leader: E. Ranieri, Università di Foggia).

Principal Investigator, Progetto PRIN 2006, MiUR (2006061954_004). **Project title::** Tumor endothelial Cells, Endothelial Progenitor Cells and Renal Cancer: role of CCI-779 in inhibiting tumor angiogenesis in xenograft experimental model of renal cell carcinoma. (Funding : 25.000,00€). (Project leader : G. Camussi, University of Turin, Italy).

Co-Investigator and Project Leader, Chair of Clinical Pathology, University of Foggia, Bioagromed, Progetto Strategico della Regione Puglia : “Research and development of new bioinformatic and biotechnologic tools to analyse gene and protein profile expression of cancer and detect new biomarkers for early diagnosis of colorectal, renal, and oral cavity neoplasia. **Project title:** NOVEL BIOMARKERS IDENTIFICATION IN TISSUES AND BIOLOGICAL FLUIDS: PROTEOCHIP DEVELOPMENT AND PRODUCTION FOR EARLY DIAGNOSIS IN CANCER PATIENTS, 2006 –2007. (PS_012 - Program Leader : Dr. F. Perri, IRCCS, S. Giovanni Rotondo, FG, Italy, total Funding : 1.185.000,00 €).

Principal Investigator “Quota Progetti (Fondi ex 60%) Progetto di Ricerca Finanziabile con fondi di Ateneo, “Rapamicina e carcinoma renale: nuovo target molecolare”, University of Foggia (2005).

Co-Investigator and Project Leader of Sezione di Nefrologia dell’Università di Bari, D.E.T.O. of the project Istituto Superiore di Sanità’ :“Vaccine based on autologous Dendritic cells pulsed with lysate of renal tumor cell line or renal tumor tissue.”, Attività di ricerca finalizzata (Art. 12 del D.L.gs. 502/92 integrato dall’art. 12 bis del D.Lgs. 229/99), 2004 –2005. (Program Leader : IRCCS).

Co-Investigator and Project Leader of Sezione di Chirurgia e Trapianti di fegato dell'Università di Bari, D.E.T.O. of the project Istituto Superiore di Sanità: "Utilizzo di cellule dendritiche di derivazione monocitica (CD14+) e staminale (CD34+) per l'immunoterapia del cancro, "Attività di ricerca finalizzata (Art. 12 del D.L.gs. 502/92 integrato dall'art. 12 bis del D.Lgs. 229/99), 2001 –2003. (Program Leader : Prof. L. Gesualdo).

Co-Investigator Fondi ex 60% Progetto di Ricerca Finanziabile con fondi di Ateneo, "Sviluppo di nuovi protocolli di immunoterapia per il trattamento del carcinoma renale", Università degli Studi di Bari (2001). (Program Leader : Prof. L. Gesualdo).

Co-Investigator of the Grant Program National Institutes of Health: "Vaccine-Induced evolution of T cell immunity in RCC", SPORE in renal cancer., 1998-2000 (Principal Investigator: Walter J. Storkus).

Co-Investigator of the Grant Program National Institutes of Health 2R01: "Dendritic Cell Strategies to Elicit Tumor Reactive T Cells". CA 57840-05; 4/01/1998-3/31/2003; (Principal Investigator: Walter J. Storkus)

Co-Investigator of the Grant Program National Institutes of Health 2P01 dal titolo "IL-12: A heterodimeric cytokine for gene therapy and to enhance antitumor effector cell function".CA 68067-05, 7/1/2000-6/30/2004; (Program Leaders: Michael T. Lotze and Walter J. Storkus).

Co-investigator of the Progetto Finalizzato Biotecnologie e Biostrumentazione del CNR, Biotechnology for the production of drugs and for the control of cell differentiation. (Program Leader F.P. Skena).

Co-investigator of the Progetto Finalizzato Biotecnologie e Biostrumentazione del CNR - Sottoprogetto: "Application of Biotechnologies to cell culture and organ transplantation"(Program Leader F.P. Skena).

Co-Investigator of the Baxter Extramural Grant Program : "Peritoneal dialysis fluids and membrane longevity: a clinical and molecular biology prospective study for predicting peritoneal fibrosis" (1997-2000, Principal Investigator Prof. Gesualdo).

Co-Investigator of the Baxter Extramural Grant Program : "Therapeutic modulation of cytokine expression in IgA nephropathy: a clinical and histopathological prospective study" (1995-1998; Principal Investigator Prof. Skena).

Co-Investigator of the Baxter Extramural Grant Program : "Prospective study on cytokine renal expression in human proliferative glomerulonephritides. Search for pathogenetic factors and prognostic indicators" (1992-1995; Principal Investigator Prof. Skena).

COLLABORATIONS:

Department of Surgery, University of Pittsburgh, USA; Institute of Pathology, Case Western Reserve University, Cleveland, OH, USA; Department of Medicine, University of Texas, San Antonio, USA; Department of Haemathology/Oncology, University of Mainz, Germany, Department of Medicine, Excellent Center for Research, Transfer and High Education DENohe, University of Florence, Department of Internal Medicine and Research Centre for Experimental Medicine (CeRMS), University of Turin. Italy.

PATENTS

- 2008** Title: **Renal cell carcinoma cell line and use thereof**. International deposit and European Patent N° PCT/EP2006/067631, on 20.10.2006. **Inventors: Elena Ranieri**, Loreto Gesualdo, Wolfgang Herr, Michele Battaglia. . Applicants: University of Bari, University of Foggia
- 2005** Title : Linea cellulare di carcinoma renale e suo uso". Industrial Patent No. MI2005 A002018, 21.10.05. Inventors: **E Ranieri**, L Gesualdo, W Herr, M Battaglia. Applicants: University of Bari, University of Foggia.
- 2005** Title : Metodo per il dosaggio del fattore di crescita epidermico (EGF) e del peptide-1 chemiotattico dei monociti umani (MCP-1) in un campione biologico e relativo kit diagnostico. Industrial Patent No. RM2005 A000195, 22.04.05. Inventors: FP Schena, L Gesualdo, G Grandaliano, **E Ranieri**. Applicant: Apuliabiotech scrl.
- 2012** Patent licensed to European Collection of Cell Cultures (ECACC), Public Health England, Porton Down, Salisbury SP4 0JG, UK
<http://www.phe-culturecollections.org.uk/collections/ecacc.aspx>

Spin-Off

- 2008 – pres Partner “BiocomLab” S.r.l. - Spin-Off**

PUBLICATIONS

442 publications, 130 edited on international journals. **Original papers : 130** (Journal Citation Report (ISI). (Total Impact factor >**480**; impact factor mean: **5,10**; H index :**35**; total citations : **4530** on 19.6.20).

Papers: 129	Cites/paper: 22.84	h-index: 33	AWCR: 275.54
Citations: 3401	Cites/author: 651.18	g-index: 53	AW-index: 16.60
Years: 22	Papers/author: 30.75	hc-index:18	AWCRpA: 59.55
Cites/year: 84.17	Authors/paper: 4.37	hl-index:6.23	e-index: 39.33
		hl,norm:16	hm-index: 11.30

Sections

A.	Original Papers reported on the Journal Citation Report (ISI)	95
B.	Reviews, editorials and book chapters	16
C.	International Proceedings	14
D.	International Abstracts	155
E.	National reviews, editorials and book chapters	20
F.	National Proceedings	19
G.	National Abstracts	123
	Total	442

A. Original papers

- 95A.** GS. Netti, L. Santangelo, L. Paulucci, G. Piscopo, D.D. Torres, V. Carbone, P. Giordano, F. Spadaccino, G. Castellano, G. Stallone, L. Gesualdo, M. Chironna, **E. Ranieri** and M. Giordano.
Low C3 serum levels predict severe forms of STEC-HUS with neurologic involvement.
In press **Frontiers in Medicine** 2020
- 94A.** F. Rascio, P. Pontrelli, GS. Netti, E. Manno, B. Infante, S. Simone, G. Castellano, **E. Ranieri**, M. Seveso, E. Cozzi, L. Gesualdo, G. Stallone, G. Grandaliano.
IgE-Mediated Immune Response and Antibody-mediated Rejection.
In press **CJASN** 2020
- 93A.** G.S. Netti, G. Lucarelli, F. Spadaccino, G. Castellano, M. Gigante, C. Divella, M.T. Rocchetti, F. Rascio, V. Mancini, G. Stallone, G. Carrieri, L. Gesualdo, M. Battaglia, **E. Ranieri**.
PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma.
Ageing (Albany NY). 2020 Apr 28;12. doi: 10.18632/aging.103169. [Epub ahead of print] (**Impact Factor: 5,51**)

- 92A.** GS. Netti, M. Rotondi, A. Di Lorenzo, D. Papantonio, A. Teri, M. Schirone, F. Spadaccino, L. Croce, B. Infante, R. Perulli, F. Coperchini, M.T. Rocchetti, G. Iannelli F. Fortunato, R. Prato, L. Gesualdo, G. Stallone, **E. Ranieri** and G. Grandaliano (co-seniorship)
Nocturnal hemodialysis is associated with a reduced occurrence of low triiodothyronine serum levels in hemodialyzed patients.
Clin Kidney J 2019.
- 91A.** GS. Netti, Barbara I., F. Spadaccino, G. Godeas, MG. Corallo, C. Prisciandaro, L. Croce, M. Rotondi, L. Gesualdo, G. Stallone, G. Grandaliano and **E. Ranieri**.
Serum levels of BAFF and APRIL predict clinical response in anti-PLA2R positive primary membranous nephropathy.
J Immunol Res. 2019 Nov 5;2019:8483650. doi: 10.1155/2019/8483650. eCollection 2019.
- 90A.** G.S. Netti, F. Sangregorio, F. Spadaccino, F. Staffieri, A. Crovace, B. Infante, A. Maiorano, G. Godeas, G. Castellano, A.M. Di Palma, C. Prattichizzo, A. Cotoia, L. Mirabella, L. Gesualdo, G. Cinnella, G. Stallone, **E. Ranieri** and G. Grandaliano. (co-seniorship)
LPS removal reduces CD80-mediated albuminuria in critically ill patients with gram-negative sepsis.
Am J Physiol Renal Physiol. 2019 Jan 23. doi: 10.1152/ajprenal.00491.2018. (Impact Factor 3,6)
- 89A.** G. Lucarelli, M. Rutigliano, F. Sallustio, D. Ribatti, A. Giglio, M: Lepore Signorile, V. Rossi, P. Sanese, A. Napoli, E. Maiorano, C. Bianchi, R.A. Perego, M. Ferro, **E. Ranieri**, G. Serino, L.N. Bell, P. Ditunno, C. Simone, M. Battaglia.
Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma.
Aging 2018 Dec 11;10(12):3957-3985. doi: 10.18632/aging.101685 (Impact Factor 5,2)
- 88A.** C. Cafiero, M. Gigante, G. Brunetti, S. Simone, A. Oranger, **E. Ranieri**, S. Colucci, G.B. Pertosa, M. Grano, L. Gesualdo.
Inflammation induces osteoclast differentiation from peripheral mononuclear cells in chronic kidney disease patients: crosstalk between the immune and bone system.
Nephrol Dial. Transplant. 2018 Jan 1;33(1):65-75. doi: 10.1093/ndt/gfx222 (Impact factor 4,47).
- 87A.** Papale M., Vocino G., Gigante M., Lucarelli G., Rutigliano M., Rocchetti M.T., Pesce F., Sanguedolce F., Bufo L., Battaglia M., Stallone G., Grandaliano G., Carrieri G., Gesualdo L., **E. Ranieri**.
Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma.
Oncotarget. 2017 Jun 20;8(25):40412-40424. doi: 10.18632/oncotarget.16341. (Impact Factor 5,168)
- 86A.** Lucarelli G, Rutigliano M, Ferro M, Giglio A, Intini A, Triggiano F, Palazzo S, Gigante M, Castellano G, **Ranieri E**, Buonerba C, Terracciano D, Sanguedolce F, Napoli A, Maiorano E, Morelli F, Ditunno P, Battaglia M.
Activation of the kynurenine pathway predicts poor outcome in patients with clear cell - renal cell carcinoma.
Urol Oncol. 2017 Mar 27. pii: S1078-1439(17)30095-9. doi: 10.1016/j.urolonc.2017.02.011. (Impact factor 2.921)
- 85A.** Mastropasqua F, Marzano F, Valletti A, Aiello I, Di Tullio G, Morgano A, Liuni S, **Ranieri E**, Guerrini L, Gasparre G, Sbisà E, Pesole G, Moschetta A, Caratozzolo MF, Tullo A.
TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.
Mol Cancer. 2017 Mar 21;16(1):67. doi: 10.1186/s12943-017-0634-7. (Impact factor 5,88)
- 84A.** M. Gigante, S. Diella, L. Santangelo, E. Trevisson, M.J. Acosta, M. Amatruda, G. Finzi, G. Caridi, L. Murer, M. Accetturo, **E. Ranieri**, G.M. Ghiggeri, M. Giordano, G. Grandaliano, L. Salviati, L. Gesualdo.
Further phenotypic heterogeneity of CoQ10 deficiency associated with Steroid Resistant Nephrotic Syndrome and novel COQ2 and COQ6 variants.

Clin Genet, 2017 Jan 2. doi: 10.1111/cge.12960. [Epub ahead of print] **(Impact factor 3,892)**

- 83A.** Prattichizzo C, Gigante M, Pontrelli P, Stella A, Rocchetti MT, Gigante M, Maiorano E, Herr W, Battaglia M, Gesualdo L, Ranieri E.
Establishment and characterization of a highly immunogenic human renal carcinoma cell line
Int J Oncol. 2016 May 27. doi: 10.3892/ijo.2016.3544. [Epub ahead of print] (Impact factor 3,01)
- 82A.** Margherita Gigante, P. Pontrelli, W. Herr, Maddalena Gigante, M. D'avenia, G. Zaza, E. Cavalcanti, M. Accetturo, G. Lucarelli, G. Carrieri, M. Battaglia, W.J. Storkus, L. Gesualdo and E. Ranieri
miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.
J Transl Med, 2016;11;14(1):84 **(Impact factor 3,93)**
- 81A.** Gallo C, Ciavarella D, Santarelli A, **Ranieri E**, Colella G, Lo Muzio L, Lo Russo L.
Potential Salivary Proteomic Markers of Oral Squamous Cell Carcinoma.
Cancer Genomics Proteomics. 2016 01-02;13(1):55-61.
- 80A.** L. Lucarelli, M. Rutigliano, F. Dolce, V. Galleggiante, A. Giglio, S. Cagiano, P. Bufo, E. Maiorano, D. Ribatti, **E. Ranieri**, M. Gigante, L. Gesualdo, M. Ferro, O. Decobelli, G. Di Lorenzo, S. Deplacido, S. Palazzo, C. Bettocchi, P. Ditunno, M. Battaglia.
Increased expression of the autocrine motility factor is associated with poor prognosis in patients with clear cell renal cell carcinoma.
Medicine (Baltimore). 2015 Nov;94(46):e2117. doi: 10.1097. **(Impact Factor 5, 723)**
- 79A.** M. Gigante, G. Lucarelli, C. Divella, GS Netti, P. Pontrelli, C. Cafiero, G. Grandaliano, G. Castellano, M. Rutigliano, G. Stallone, C. Bettocchi, P. Ditunno, L. Gesualdo, Michele Battaglia, **E. Ranieri**.
Soluble serum α Klotho is a potential predictive marker of disease progression in clear cell Renal Cell Carcinoma
Medicine (Baltimore). 2015 Nov;94(45):e1917. doi: 10.1097. **(Impact Factor 5, 723)**
- 78A.** Faienza MF, Brunetti G, Ventura A, Piacente L, Messina MF, De Luca F, Ciccarelli M, Oranger A, Mori G, Natale MP, Gigante M, **Ranieri E**, Gesualdo L, Colucci S, Cavallo L, Grano M.
Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner's Syndrome.
Bone. 2015 Jul 21;81:228-236. doi: 10.1016/j.bone.2015.07.021. [Epub ahead of print] **(Impact Factor 3.97)**
- 77A.** Rascio F, Pontrelli P, Accetturo M, Oranger A, Gigante M, Castellano G, Gigante M, Zito A, Zaza G, Lupo A, **Ranieri E**, Stallone G, Gesualdo L, Grandaliano G.
A Type I Interferon Signature Characterizes Chronic Antibody-Mediated Rejection in Kidney Transplantation.
J Pathol. 2015 Apr 29.
doi:10.1002/path.4553. [Epub ahead of print] PubMed PMID: 25925804. **(Impact Factor 7.33)**
- 76A.** Pontrelli P., M. Cariello, F. Rascio, R. Verrienti, G. Castellano, C. Divella, G. Stallone, M. Gigante, T. Tataranni, E. Ranieri, L. Gesualdo, G. Grandaliano. Thrombin may modulate dendritic cells activation in kidney transplant recipients with delayed graft function.
Nephrol Dial Transplant. 2015 **(Impact Factor 3.488)**
- 75A.** Vavallo A, Simone S, Lucarelli G, Rutigliano M, Galleggiante V, Grandaliano G, Gesualdo L, Campagna M, Cariello M, **Ranieri E**, Pertosa G, Lastilla G, Selvaggi FP, Ditunno P, Battaglia M. Pre-existing Type 2 Diabetes Mellitus Is an Independent Risk Factor for Mortality and Progression in Patients With Renal Cell Carcinoma.
Medicine (Baltimore). 2014 Dec;93(27):e183. doi:10.1097/MD.000000000000183. PubMed PMID: 25501064.73A.

- 74A.** M.F. Caratozzolo, A. Valletti, M. Gigante, I. Aiello, F. Mastropasqua, F. Marzano, P. Ditunno, G. Carrieri, H. Simonnet, A.M. D'Erchia, **E. Ranieri**, G. Pesole, E. Sbisà, A. Tullo. TRIM8 anti-proliferative action against chemo-resistant Renal Cell Carcinoma.
Oncotarget 2014 Sep 15;5(17):7446-57. **(Impact Factor 6.636)**
- 73A.** Rocchetti MT, Alfaraano M, Varraso L, Di Paolo S, Papale M, **Ranieri E**, Grandaliano G, Gesualdo L. Two dimensional gel phosphoproteome of peripheral blood mononuclear cells: comparison between two enrichment methods
Proteome Sci. 2014 Sep 9;12(1):46. doi: 10.1186/s12953-014-0046-1. eCollection 2014. **(Impact Factor 1.878)**
- 72A.** G. Stallone, L. Cormio, G.S. Netti, B. Infante, O. Selvaggio, G. Di Fino, **E. Ranieri**, F. Bruno, C. Praticchizzo, F. Sanguedolce, S. Tortorella, P. Bufo, G. Grandaliano, G. Carrieri. Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer.
Cancer Res. 2014 Aug 15;74(16):4230-8. doi: 10.1158/0008-5472.CAN-14-0369. Epub 2014 Jun 20. PubMed PMID: 24950910. **(Impact Factor 9.284)**
- 71A.** Netti G.S., Praticchizzo C., Montemurno E., Simone S., Caffiero C, Stallone G., **Ranieri E.**, Grandaliano G., Gesualdo L. Exposure to low- vs iso-osmolar contrast agents reduces NADPH-dependent Reactive Oxygen Species (ROS) generation in a cellular model of renal injury.
Free Radic Biol Med. 2013 Dec 1;68C:35-42. doi: 10.1016/j.freeradbiomed.2013.11.016. [Epub ahead of print]. **(Impact Factor: 5.271)**
- 70A.** Valletti A, Gigante M, Palumbo O, Carella M, Divella C, Sbisà E, Tullo A, Picardi E, D'Erchia Am, Battaglia M, Gesualdo L, Pesole G, **Ranieri E.** Genome-wide analysis of differentially expressed genes and splicing isoforms in clear cell renal cell carcinoma.
PLoS One. 2013 Oct 23;8(10):e78452. doi:10.1371/journal.pone.0078452. pubmed pmid: 24194935; pubmed central pmcid: pmc3806822. **(Impact Factor: 3.730)**
- 69A.** G. Stallone, P. Pontrelli, B. Infante, Margherita Gigante, G.S. Netti, **E. Ranieri**, G. Grandaliano, L. Gesualdo. Rapamycin induces ILT3^{high} ILT4^{high} dendritic cells promoting a new immunoregulatory pathway.
Kidney Int. 2013 Oct 9. doi: 10.1038/ki.2013.337. [epub ahead of print] pubmed pmid: 24107844. **(Impact Factor: 7.916)**
- 68A.** Panza A, Paziienza V, Ripoli M, Benegiamo G, Gentile A, Valvano MR, Augello B, Merla G, Praticchizzo C, Tavano F, **Ranieri E**, di Sebastiano P, Vinciguerra M, Andriulli A, Mazzoccoli G, Piepoli A. Interplay between SOX9, beta-catenin and PPAR gamma activation in colorectal cancer.
Biochim Biophys Acta. 1833(8):1853-65 2013 Aug. doi: 10.1016/j.bbamcr.2013.04.004. Epub 2013 Apr 11. **(Impact Factor: 5.538)**
- 67A.** Muscarella LA, D'Agruma L, la Torre A, Gigante M, Coco M, Parrella P, Battaglia M, Carrieri G, Carella M, Leopoldo Z, Fazio VM, Gesualdo L, **Ranieri E.** VHL gene alterations in Italian patients with isolated renal cell carcinomas.
Int J Biol Markers. 28;28(2):208-15 2013 Jun. doi: 10.5301/jbm.5000011. [Epub ahead of print] PubMed PMID: 23558940, 2013 Apr **(Impact Factor: 1.48)**
- 66A.** M. Gigante, M. d'Altilia, E. Montemurno, S. Diella, F. Bruno, G.S. Netti, **E. Ranieri**, G. Stallone, B. Infante, G. Grandaliano, L. Gesualdo. Branchio-Oto-Renal Syndrome (BOR) associated with focal glomerulosclerosis in a patient with a novel EYA1 splice site mutation.
BMC Nephrol. 18;14:60, 2013 Mar **(Impact Factor: 2.176)**

- 65A.** L. Lo Russo, M. Papale, D. Perrone, **E. Ranieri**, C. Rubini, G. Giannatempo, A. Santarelli, G. Colella, L. Lo Muzio. Salivary proteomic signatures of oral squamous cell carcinoma. *European J Inflammation* 10(1) :61-70. 2012 Jan-Apr (**Impact Factor: 5,23**)
- 64A.** Gianluigi Mazzoccoli, Ada Piepoli, Massimo Carella, Anna Panza, Valerio Paziienza, Giorgia Benegiamo, Orazio Palumbo, **Elena Ranieri**. Altered expression of the clock gene machinery in kidney cancer patients. *Biomedicine & Pharmacotherapy* 66(3):175-9. 2012 Apr (**Impact Factor:2.208**)
- 63A.** A. Consiglio, M. Carella, G. De Caro, G. Delle Foglie, C. Givannelli, G. Grillo, M. Ianigro, F. Liciulli, O. Palombo, A. Piepoli, **E. Ranieri**, S. Liuni.
BEAT: Bioinformatics Exon Array Tool to store, analyze and visualize Affymetrix GeneChip Human Exon Array data from disease experiments. *Bioinformatics* 13 (Suppl 4):S21. 2012 (**Impact Factor:3.03**)
- 62A.** M de Martino, Maddalena Gigante, L. Cormio, C. Prattichizzo, E. Cavalcanti, Margherita Gigante, V. Ariano, G.S. Netti, E. Montemurno, V. Mancini, M. Battaglia, L. Gesualdo, G. Carrieri, **E. Ranieri**. JAK3 in clear cell renal cell carcinoma: mutational screening and clinical implications. *Urol Oncol*. 2011 Aug 23. (**Impact Factor:3.172**)
- 61A.** M. Gigante, G. Caridi, E. Montemurno, R. Trunzo, A. Schirinzi, F. Aucella, G. Messina, L. Massella, **E. Ranieri**, G.M. Ghiggeri, L. Gesualdo. TRPC6 mutations in children and steroid resistant nephritic syndrome and atypical phenotypes. *Clin J Am Soc Nephrol*, 6(7):1626-34. 2011 Jul (**Impact Factor: 4.763**)
- 60A.** A. Loverre, C. Divella, G. Castellano, T. Tataranni, G. Zaza, M. Rossigni, P. Ditunno, M. Battaglia, S. Palazzo, M. Gigante, **E. Ranieri**, F. P. Schena and G. Grandaliano. T helper 1, 2 and 17 cell subsets in renal transplant patients with delayed graft function. *Transplant International*. Mar;24(3):233-42. 2011 (**Impact Factor:3,254**)
- 59A.** E. Cavalcanti, M. Gigante, V. Mancini, M. Battaglia, P. Ditunno, C. Capobianco, R.I. Cincione, F.P. Selvaggi, W. Herr, W.J. Storkus, L. Gesualdo, **E. Ranieri**. JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8+ T cells in renal cell carcinoma patients.
J Biomed Biotechnol. 2010;2010:935764. 2010. (**Impact Factor: 2.56**)
- 58A.** Stallone G., Infante B., Pontrelli P., **Ranieri E.**, Loverre A., Schena A., Cormio L., Carrieri G., Schena F.P., Grandaliano G., Gesualdo L. ID2-VEGF-related Pathways in the Pathogenesis of Kaposi's Sarcoma: A Link Disrupted by Rapamycin.
Am J Transplant. 9(3):558-566. 2009. (**Impact Factor: 6.559**)
- 57A.** Gigante M, Pontrelli P, Montemurno E, Roca L, Aucella F, Penza R, Caridi G, **Ranieri E**, Ghiggeri GM, Gesualdo L. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS).
Nephrol Dial Transplant. 24(6):1858-64. 2009 Jun. (**Impact Factor: 3.568**)
- 56A.** Gigante M., Blasi A., Loverre A., Mancini V., Battaglia M., Selvaggi FP., Maiorano E., Castellano G., Storkus WJ., Gesualdo L., **Ranieri E**. Dysfunctional DC subsets in RCC patients: Ex vivo correction to yield an effective anti-cancer vaccine.
Mol Immunol. 46(5):893-901, 2008 (**Impact Factor: 3.555**)
- 55A.** A. Schirinzi, M. Centra, C. Prattichizzo, M. Gigante, M. De Fabritiis, V. Giancaspro, F. Petrarulo, R. Santacroce M. Margaglione, L. Gesualdo, **E. Ranieri**. Identification of GLA gene deletions in Fabry patients by Multiplex Ligation-dependent Probe Amplification (MLPA)
Mol Genet Metab, 94: 382-385, 2008 (**Impact Factor: 2.629**)
- 54A** M. Gigante, M. Kandic, A.K. Wesa, E. Cavalcanti, M. Dambrosio, V. Mancini, M. Battaglia, L. Gesualdo, W.J. Storkus, **E. Ranieri**. Interferon-alpha (IFN- α)-conditioned DC preferentially stimulate Type-1 and limit Treg-type *in vitro* T cell responses from RCC patients.

J. Immunother, 31(3):254-262, 2008. Feb 29; [Epub ahead of print] **(Impact factor: 3.662).**

- 53A** M. Landriscina, S. Altamura, L. Roca, M. Gigante, A. Piscazzi, E. Cavalcanti, N. Maiorano, M. Cignarelli, L. Gesualdo, **E. Ranieri**. Reverse Transcriptase Inhibitors Induce Cell Differentiation and Enhance the Immunogenic Phenotype in Human Renal Clear-cell Carcinoma.
Int. J. Cancer, 122(12):2842-2850, 2008. **(Impact Factor: 4.734)**
- 52A** P. Pontrelli, M. Rossini, B. Infante, G. Stallone, A. Schena, A. Loverre, M. Ursi, R. Verrienti, A. Maiorano, **E. Ranieri**, L. Gesualdo, P. Ditunno, F.P. Schena, G. Grandaliano. Rapamycin inhibits pai-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy.
Transplantation, 85(1):125-134, 2008 **(Impact Factor:3.816)**
- 51A** M.T. Rocchetti, M. Centra, M. Papale, G. Bortone, C. Palermo, D. Centonze, **E. Ranieri**, S. Di Paolo and L. Gesualdo. Urine protein profile of IgA Nephropathy patients may predict the response to Ace-Inhibitor therapy.
Proteomics, 8(1):206-16, 2008 **(Impact Factor: 4.586)**
- 50A** Torres DD, Rossini M, Manno C, Mattace-Raso F, D'Altri C, **Ranieri E**, Pontrelli P, Grandaliano G, Gesualdo L, Schena FP. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy.
Kidney Int. 2007 Oct 17; **(Impact Factor 6.418)**
- 49A.** M. Papale, M.C. Pedicillo; S. Di Paolo, B.J. Thatcher; L. Lo Muzio, P. Bufo, M.T. Rocchetti; M. Centra, **E. Ranieri**, L. Gesualdo. Saliva analysis by Surface Enhanced Laser Desorption /Ionization Time Of Flight Mass Spectrometry (SELDI-TOF/MS): from sample collection to data analysis.
Clin Chem Lab Med, 2008;46(1):89-99. **(Impact Factor 1,918)**
- 48A.** A. Loverre, C. Capobianco, **E. Ranieri**, A. Crovace, P. Di tonno, M. Battaglia, G. Stallone, A. Schena, B. Infante, FP Schena, L. Gesualdo, G. Grandaliano. Ischemia-reperfusion injury induces abnormal dendritic cell traffic in transplant kidney with delayed graft function.
Kidnet Int. 72(8):994-1003, 2007 **(Impact Factor 4.922)**
- 47A.** L. Roca, S. Di Paolo, **E. Ranieri**, L. Gesualdo. Dexamethasone modulates Interleukin-12 production by inducing Monocyte Chemoattractant Protein 1 In human dendritic cells.
Immunol Cell Biol. 85(8):610-6.2007. **(Impact Factor: 2.482)**
- 46A.** D. Leogrande, A. Teutonico, **E. Ranieri**, M. Saldarelli, L. Gesualdo, F.P. Schena, S. Di Paolo. Sustained suppression of ribosomal protein S6 Kinase activation in PBMC by rapamycin correlates with histologic severity of chronic kidney allograft lesions.
Am J Kidney Dis 50: 314-325, 2007 **(Impact Factor 3.981)**
- 45A.** Fiore N, Castellano G, Blasi A, Capobianco C, Loverre A, Montinaro V, Netti S, Torres D, Manno C, Grandaliano G, **Ranieri E**, Schena FP, Gesualdo L. Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis.
Mol Immunol. 45(1):259-65, 2007. **(Impact Factor: 4.307)**
- 44A.** M. Papale, M.C. Pedicillo, B.J. Thatcher, S. Di Paolo, L. Lo Muzio, P. Bufo, M.T. Rocchetti, M. Centra, **E. Ranieri**, L. Gesualdo. Urine profiling by SELDI-TOF/MS: monitoring of the critical steps in sample collection, handling and analysis.
J. Chromatography B Analyt Technol Biomed Life Sci, 856 (1-2):205-13, 2007 **(Impact Factor: 2.647)**
- 43A.** Di Paolo S., Teutonico A., **Ranieri E.**, Gesualdo L., Schena FP. Antitumor Efficacy of Rapamycin is Associated with Prolonged Inactivation of Ribosomal Protein S6 Kinase and AKT in PBMC of Renal Transplant Recipients with Kaposi's Sarcoma.
Am J Kidney Dis, 49: 462-470, 2007 **(Impact Factor 4.412)**

- 42A.** S. Kausche, T. Wehler, E. Schnürer, V. Lennerz, W. Brenner, S. Melchior, S. Strand, M. Gröne, R. Meyer, **E. Ranieri**, C. Huber, C. S. Falk, and W. Herr. Superior antitumor in vitro responses of allogeneic matched sibling compared to autologous patient CD8⁺ T cells.
Cancer Res, 66(23):11447-54, 2006. **(Impact Factor 7.616)**
- 41A.** M. Gigante, **E. Ranieri**, G. Cerullo, L. Calabresi, A. Iolascon, G. Assmann, L. Morrone, F.P. Schena, L. Gesualdo. Familial lecithin:cholesterol acyltransferase (LCAT) deficiency: a novel mutation associated with a common variant.
J. Nephrol. 19(3):375-81.2006. **(Impact Factor 1.317)**
- 40A.** L. Vujanovich, **E. Ranieri**, A. Gambotto, WC Olson, JM Kirkwood, W.J. Storkus. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor-antigen derived peptides or recombinant protein effectively stimulate specific Type-1 CD4⁺ T cell responses from normal donors and melanoma patients in vitro.
Cancer Gene Ther. 13(8):798-805, 2006. **[Epub ahead of print] (Impact Factor 3.000)**.
- 39A.** P. Pontrelli, M. Ursi, **E. Ranieri**, C. Capobianco, F.P. Schena, L. Gesualdo, G. Grandaliano. CD40L Proinflammatory and Profibrotic Effects on Proximal Tubular Epithelial Cells: Role of NF-κB and Lyn.
J. Am. Soc. Nephrol. 17:627-736, 2006. **(Impact Factor 7.240)**.
- 38A.** G. Stallone, A. Schena, B. Infante, S. Di Paolo, A. Loverre, G. Maggio, **E. Ranieri**, L. Gesualdo, F.P. Schena, G. Grandaliano. Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
New Engl. J. Med. 352: 1317-23, 2005. **(Impact Factor 38.570)**.
- 37A.** A. Dörrschuck, A. Schmidt, E. Schnürer, M. Glückmann, C. Albrecht, C. Wölfel, V. Lennerz, A. Lifke, C. Di Natale, **E. Ranieri**, L. Gesualdo, C. Huber, M. Karas, T. Wölfel, W. Herr. CD8⁺ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA-class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.
Blood 104:2591-2599, 2004 **(Impact Factor 9.782)**.
- 36A.** A. Loverre, P. Ditunno, A. Crovace, L. Gesualdo, **E. Ranieri**, P. Pontrelli, G. Stallone, B. Infante, A. Schena, S. Di Paolo, C. Capobianco, M. Ursi, S. Palazzo, M. Battaglia, F.P. Selvaggi, F. P. Schena, G. Grandaliano. Ischemia-Reperfusion Induces Glomerular And Tubular Activation Of Pro-Inflammatory And Anti-Apoptotic Pathways: Differential Modulation By Rapamicin.
J. Am. Soc. Nephrol. 15:2675-2686, 2004 **(Impact Factor 6.644)**.
- 35A.** P. Pontrelli, M. Ursi, **E. Ranieri**, G. Ghosh-Choudhury, L. Gesualdo, F.P. Schena, G. Grandaliano. JUN-N-terminal kinase regulates the profibrotic effect of thrombin in proximal tubular epithelial cells.
Kidney Int 65 : 2249-2261, 2004 **(Impact factor 4.790)**.
- 34A.** T. Tatsumi, C.J. Herrem, W.C. Olson, J.H. Finke, R.M. Bukowski, M.S. Kinch, **E. Ranieri**, W.J. Storkus. Disease stage variation in CD4⁺ and CD8⁺ T cell-reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma.
Cancer Res. 63: 4481-4489, 2003 **(Impact Factor 8.649)**.
- 33A.** G. Grandaliano, P. Pontrelli, G. Cerullo, R. Monno, **E. Ranieri**, M. Ursi, A. Loverre, L. Gesualdo, F.P. Shena. Protease-activated receptor-2 expression in IgA nephropathy: a potential role in the pathogenesis of interstitial fibrosis and glomerulosclerosis.
J. Am. Soc. Nephrol. 14 : 2072-2083, 2003 **(Impact Factor 7.499)**.
- 32A.** T. Tatsumi, L. S. Kierstead, **E. Ranieri**, L. Gesualdo, F.P. Schena, J.H. Finke, R.M. Bukowski, V. Brusica, J. Sidney, A. Sette, T.F. Logan, Y.L. Kasamon, J.M. Kirkwood, W. J. Storkus. MAGE-6 encodes HLA-DR1*0401-presented epitopes recognized by CD4⁺ T cells from patients with melanoma or RCC.
Clin. Cancer Res. 9: 947-954, 2003 **(Impact Factor 6.511)**.

- 31A.** T. Tatsumi, L.S. Kierstead, **E. Ranieri**, L. Gesualdo, F.P. Schena, James H. Finke, R.M. Bukowski, J. Mueller-Berghaus, J.M. Kirkwood, W. W. Kwok, W. J. Storkus. Disease-Associated Bias in Th1/Th2 CD4⁺ T Cell Responses Against MAGE-6 in HLA-DRB1*0401⁺ Patients With Renal Cell Carcinoma or Melanoma.
J. Exp. Med. 196 : 619-628 , 2002 (**Impact Factor 15.837**)
- 30A.** Kierstead L.S., **Ranieri E.**, Olson W., Brusica V., Sidney J., Sette A., Kasamon Y.L., Slingluff C.L. Jr, Kirkwood J.M., Storkus W.J. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4⁺T cells.
Br. J. Cancer. 85:1738-1745, 2001 (**Impact factor 3.942**)
- 29A.** G. Grandaliano, S. Di Paolo, R. Monno, G. Stallone, **E. Ranieri**, P. Pontrelli, L. Gesualdo, F.P. Schena. Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy.
Transplantation, 72: 1437-1443, 2001 (**Impact Factor : 4.184**).
- 28A.** **E. Ranieri**, L. Gesualdo, G. Grandaliano, E. Maiorano, F. P. Schena. The role of α -Smooth muscle actin and Platelet derived growth factor- β receptor in the progression of renal damage in human IgA Nephropathy.
J. Nephrol. 14 :253-262, 2001 (**Impact Factor : 1.241**).
- 27A.** R. Monno, G. Grandaliano, R. Faccio, C. Martino, **E. Ranieri**, L. Gesualdo, F.P. Schena. Activated coagulation factor X: A novel mitogenic stimulus for human mesangial cells.
J. Am. Soc. Nephrol. 12 : 891-899, 2001(**Impact Factor:6.337**).
- 26A.** Grandaliano G, Gesualdo L, **Ranieri E**, Monno R, Schena FP. Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis.
Am J Kidney Dis. 35 : 726-738, 2000 (**Impact Factor : 3.646**).
- 25A.** W. Herr, **E. Ranieri**, W. Olson, H. Zarour, L. Gesualdo, W.J. Storkus. Mature dendritic cells pulsed with freeze-thaw lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4⁺ and CD8⁺ T lymphocyte responses.
Blood 96 :1857-1864, 2000 (**Impact Factor : 8.977**).
- 24A.** Grandaliano G, Monno R, **Ranieri E**, Gesualdo L, Schena FP, Martino C, Ursi M. Regenerative and proinflammatory effects of thrombin on human proximal tubular cells.
J. Am. Soc. Nephrol. 11: 1016-1025, 2000 (**Impact Factor : 5.745**).
- 23A.** Grandaliano G., Gesualdo L., Bartoli F, **Ranieri E**, Monno R, Leggio A, Paradies G, Caldarulo E, Infante B, Schena FP. MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy.
Kidney Int. 58: 182-192, 2000 (**Impact Factor : 4.371**).
- 22A.** **E. Ranieri**, W. Herr, A. Gambotto, W. Olson, D. Rowe, P.D. Robbins, L.S. Kierstead, S.C. Watkins, L. Gesualdo, W.J. Storkus. Dendritic cells transduced with adenoviral vector encoding the Epstein-Barr virus Latent Membrane Protein 2B: a new modality for vaccination.
J Virol. 73 :10416-10425, 1999 (**Impact Factor : 5.942**).
- 21A.** W. Herr, **E. Ranieri**, A. Gambotto, L. S. Kierstead, A.A. Amoscato, L. Gesualdo, W.J. Storkus. Identification of naturally-processed HLA-presented Epstein-Barr virus peptides recognized by CD4⁺ or CD8⁺ T lymphocytes from human blood.
Proc Natl Acad Sci U S A, 96:12033-12038, 1999 (**Impact Factor: 10.260**).
- 20A.** Maiorano E, Ciampolillo A, Gesualdo L, **Ranieri E**, Fanelli M, Viale G. Expression of transforming growth factor- β 1 in thyroid tumors
Applied Immunohistochemistry & Molecular Morphology, 7: 135-141, 1999 (**Impact Factor : 1,5**).

- 19A.** Di Paolo S, Grandaliano G, Gesualdo L, **Ranieri E**, Schena FP. Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-beta 1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells.
Clin Exp Immunol, 117:355-360, 1999 (**Impact Factor : 2.831**).
- 18A.** Gesualdo L, **Ranieri E**, Monno R, Rossiello MR, Colucci M, Semeraro N, Grandaliano G, Schena FP, Ursi M, Cerullo G. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells.
Kidney Int. 56:461-470, 1999 (**Impact Factor : 3.807**).
- 17A.** G. Grandaliano, **E. Ranieri**, R. Monno, L. Gesualdo, F.P. Schena. Ramipril inhibits in vitro human mesangial cell proliferation and platelet-derived growth factor expression.
Exp. Nephrol. 7: 229-235, 1999 (**Impact Factor : 1.411**).
- 16A.** Pertosa G, Grandaliano G, Gesualdo L, **Ranieri E**, Monno R, Schena FP. Interleukin-6, interleukin-8 and monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes.
Kidney Int. 54 : 570-579, 1998 (**Impact Factor : 3.781**).
- 15A.** S. Di Paolo, L. Gesualdo, G. Stallone, **E. Ranieri**, F. P. Schena. Renal expression and urinary concentration of EGF and IL-6 in acutely dysfunctioning kidney transplanted patients.
Nephrol. Dial. Transplant. 12:2687-2693, 1997 (**Impact Factor : 1.662**).
- 14A.** V. Montinaro, L. Gesualdo, **E. Ranieri**, R. Monno, G. Grandaliano, F.P. Schena. Renal cortical complement C3 gene expression in IgA nephropathy.
J. Am. Soc. Nephrol. 8: 415-425, 1997 (**Impact Factor : 6.121**).
- 13A.** G. Grandaliano, L. Gesualdo, **E. Ranieri**, R. Monno, G. Stallone, F.P. Schena. Monocyte chemotactic peptide-1 expression and monocytes infiltration in acute renal transplant rejection
Transplantation 63: 414-420, 1997 (**Impact Factor : 3.441**)
- 12A.** L. Gesualdo, G. Grandaliano, **E. Ranieri**, R. Monno, V. Montinaro, C. Manno, F.P. Schena. Monocyte recruitment in cryoglobulinemic membranoproliferative glomerulonephritis : a pathogenetic role for monocyte chemotactic peptide 1.
Kidney Int. 51:155-163,1997 (**Impact Factor : 4.071**).
- 11A.** S. Di Paolo, L. Gesualdo, **E. Ranieri**, G. Grandaliano, F.P. Schena. High glucose induces the overexpression of TGF- β through the activation of the PDGF loop in human mesangial cells.
Am. J. Pathol. 149:2095-2106, 1996 (**Impact Factor : 7.246**).
- 10A.** **E. Ranieri**, L. Gesualdo, F. Petrarulo, F.P. Schena. Urinary IL-6/EGF ratio : a useful prognostic marker for the progression of renal damage in IgA nephropathy.
Kidney Int. 50: 1990-2001, 1996 (**Impact Factor : 4.562**).
- 9A.** G. Grandaliano, L. Gesualdo, **E. Ranieri**, R. Monno, V. Montinaro, F. Marra, F.P. Schena. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment.
J. Am. Soc. Nephrol. 7 : 906-913, 1996 (**Impact Factor : 6.846**).
- 8A.** L. Gesualdo, S. Di Paolo, A. Calabro', S. Milani, E. Maiorano, **E. Ranieri**, G. Pannarale, F.P. Schena. Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemistry and in situ study.
Kidney Int., 49 : 656-665, 1996 (**Impact Factor : 4.562**).

- 7A.** M. Colucci, L. Gesualdo, P. Montemurro, L.G. Cavallo, M. Conese, E. Mascolo, **E. Ranieri**, S. Di Paolo, F.P. Schena, and N. Semeraro. Cultured human mesangial cells produce both type 1 and type 2 plasminogen activators inhibitors.
Thrombosis and Haemostasis,74:1516-1520,1995 (**Impact Factor: 4.464**).
- 6A.** V. Montinaro, L. Serra, S. Perissutti, **E. Ranieri**, F. Tedesco, F.P. Schena. Biosynthesis of C3 by human mesangial cells. Modulation by proinflammatory cytokines.
Kidney Int., 47 : 829-836, 1995 (**Impact Factor : 4.452**).
- 5A.** L. Gesualdo, S. Di Paolo, **E. Ranieri**, F.P. Schena. Trepidil inhibits human mesangial cells proliferation : effect on PDGF-b receptor binding and expression.
Kidney Int., 46 : 1002-1009, 1994 (**Impact Factor : 4.452**).
- 4A.** L. Gesualdo, S. Di Paolo, S. Milani, M. Pinzani, C. Grappone, **E. Ranieri**, G. Pannarale, F.P. Schena. Expression of platelet derived growth factor receptors in normal and diseased human kidney: an immunohistochemistry and in situ study.
J. Clin. Invest., 94 : 50-58, 1994 (**Impact Factor : 7.255**)
- 3A.** V. Scivittaro, L. Gesualdo, **E. Ranieri**, C. Marfella, A. Schewn, S.N. Emancipator, F.P. Schena. Profiles of immunoregulatory cytokine production in vitro in patients with IgA nephropathy and their kindred.
Clin. Exp. Immunol., 96 :311-316,1994 (**Impact Factor : 2.475**)
- 2A.** V. Scivittaro, **E. Ranieri**, M. Di Cillo, L. Aventaggiato, S. N. Emancipator and F.P. Schena. In vitro immunoglobulin production in relatives of patients with IgA Nephropathy.
Clin. Nephrol., 42: 1-8, 1994 (**Impact Factor : 1.418**).
- 1A.** F.P. Schena, V. Scivittaro, **E. Ranieri**, R. Sinico, S. Benuzzi, M. Di Cillo, L. Aventaggiato. Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy.
Clin. Exp. Immunol., 92: 139-144, 1993 (**Impact Factor: 2.475**).

B. Reviews, Editorials and Book Chapter

- 16B.** **Volume 1186 2014. Cytotoxic T Cells. Methods and Protocols. Editors** : Ranieri E.
ISBN: 978-1-4939-1157-8 (Print) 978-1-4939-1158-5 (Online)
- 15B.** Gigante M, Diella S, **Ranieri E**. Targeting the JAK/STAT Pathway in Cytotoxic T lymphocytes (CTL) by Next Generation Sequencing (NGS).
Methods Mol Biol. 2014;1186:253-68. doi: 10.1007/978-1-4939-1158-5_14. PubMed PMID: 25149312.
- 14B.** **Ranieri E**, Popescu I, Gigante M. CTL ELISPOT Assay.
Methods Mol Biol. 2014;1186:75-86. doi: 10.1007/978-1-4939-1158-5_6. PubMed PMID: 25149304.
- 13B** Gigante M, **Ranieri E**. In vitro\ex vivo generation of cytotoxic T lymphocytes.
Methods Mol Biol. 2014;1186:13-20. doi: 10.1007/978-1-4939-1158-5_2. PubMed PMID: 25149300.
- 12B.** Gigante M, Cox SN, **Ranieri E**. Negative and positive separation techniques for the isolation of antigen-specific CD8(+) T cells from blood and tumor tissue.
Methods Mol Biol. 2014;1186:1-11. doi: 10.1007/978-1-4939-1158-5_1. PubMed PMID: 25149299.11B.

- 11B. Gigante Margherita, Gesualdo Loreto, **Elena Ranieri**. TGF-Beta : a Master Switch in Tumor Immunity. **Current Pharmaceutical Design**. 2012.18(27):4126-34 (**Impact Factor:4.77**)
- 10B. Gigante M, **Ranieri E**. Role of cytotoxic CD4+ T cells in cancer immunotherapy. **Immunotherapy**. 2(5):607,2010.
- 9B. Gigante M, **Ranieri E**. TGF- β promotes immune suppression by inhibiting Tregcell apoptosis. **Immunotherapy**. 2(5):608,2010.
- 8B. Gigante M, **Ranieri E**. TLR7 and TLR8 as targets for tumor immunotherapy. **Immunotherapy**. 2(5):609,2010.
- 7B. A. D'Addabbo, M. Papale, S. Di Paolo, S. Magaldi, R. Colella, V. d'Onofrio, A. Di Palma, **E. Ranieri**, L. Gesualdo, N. Ancona. SVD Based Feature Selection and Sample Classification of Proteomic Data. **Lecture Notes in Computer Science**, 2008, Volume 5179/2008, 556-563, DOI: 10.1007/978-3-540-85567-5_69
- 6B. V. Mancini, M. Battaglia, P. Ditonno, S. Palazzo, G. Lastilla, N. Montironi, C. Bettocchi, E. Cavalcanti, **E. Ranieri**, FP. Selvaggi. Current insights in renal cell cancer pathology. **Urol Oncol**. 26(3):225-38, 2008. (**Impact Factor:3.22**)
- 5B. Di Paolo S, Leogrande D, Teutonico A, **Ranieri E**, Saldarelli M, Gesualdo L, Schena PF. In Reply. **Am J Kidney Dis**. 2008 Mar;51(3):531-532.
- 4B. M. Gigante, W.J. Storkus, **E. Ranieri**. In " Malignancies in solid organ transplant recipients", Dendritic Cells and Post-Transplant Malignancies. **International Transplantation Updates, Permanyer Publications**. 2008.
- 3B. **E. Ranieri**, M. Gigante, W.J. Storkus, L. Gesualdo. DC-based vaccine in renal cancer. **Clin Exp Immunol**, 147: 395-400, 2007.
- 2B. Kierstead, L.S., **Ranieri, E.**, Zarour, H., Kirkwood, J.M., Lotze, M.T., Whiteside, T. and Storkus, W.J. Dendritic Cell-Based Melanoma Vaccines. **In: Immunology of Ocular Tumors**, Manfred Zierhut (Ed.), Swets and Zeitlinger, Leiden, The Netherlands, 2000.
- 1B. Finke J., L.S. Kierstead, **E. Ranieri**, W.J. Storkus. Immunologic Response to RCC. **Renal Cell Carcinoma, Molecular Biology, Immunology and Clinical Management**. Editors: R.M. Bukowski and A.C. Novick. Totowa, Nj, Humana Press, Inc. 39-62, 2000.

19th June 2020

Prof. Elena Ranieri

